A stage three pharmaceutical company on the smaller cap side. If it hits, it could go from $5 to $40. He prefers a basket approach to diversify risk. If they continue to miss earnings, and there is uncertainty over trade wars this could worsen.
Stock price when the opinion was issued
Build our watch list
Sign in to track investmentsyou care about
5i Research
CNBC
iA Global Asset Management
Kingwest & Company
Stockchase Premium
A stage three pharmaceutical company on the smaller cap side. If it hits, it could go from $5 to $40. He prefers a basket approach to diversify risk. If they continue to miss earnings, and there is uncertainty over trade wars this could worsen.